drugset / Trial / NCT03604575

A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Lispro to Humalog® in Healthy Subjects

NCT03604575

Completed 28 enrolled Geropharm
RandomizedCrossoverQuadruple-blindBasic science

Summary

Pharmacokinetics and pharmacodynamics study Study of 2 formulation of insulin lispro (Insulin Lispro GEROPHARM vers. Humalog® Eli Lilly)

Timeline

Start
2016-08-22
Primary completion
2016-12-26
Completion
2016-12-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Lispro Protein / enzyme biologic 0.3 iu/kg Subcutaneous

Indications

No indication recorded.